AstraZeneca’s Emerging Markets Growth Not All About China
Executive Summary
In contrast to some of its multinational peers, AstraZeneca is steaming full ahead in its main emerging markets, logging strong growth on the back of its respiratory franchise and newer products.
You may also be interested in...
China Growth Rebounds But Pharma Starts Cutting Prices
The second quarter has been a period of stabilization for multinational drug makers in China, where the challenges of cost-cutting and a national policy to encourage domestic generics remain. Big pharmas including Novartis and Roche are voluntarily reduce prices for major products, to help them compete, reflecting a new willingness to improve patient access in the world's second-largest pharma market.
Korean Tagrisso Launch Builds On Extensive Local Data
AstraZeneca's Tagrisso has debuted in South Korea, raising hopes and treatment options for certain types of lung cancer patients, but the product will face immediate local direct competition from Hanmi’s recently launched rival olmutinib.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.